New schizophrenia drug LB-102 moves to large safety trial
Disease control
Not yet recruiting
This study tests the long-term safety of a new medication, LB-102, in 900 adults with stable schizophrenia. Participants will take the drug for 52 weeks while doctors monitor side effects and overall health. The goal is to see if LB-102 is safe for ongoing use to control schizoph…
Phase: PHASE3 • Sponsor: LB Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 09:08 UTC